Compare Biogen Inc (BIIB) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Berkshire Hathaway Inc Class B — how do they compare? Biogen Inc trades at $196.31 (market cap $28.34B), while Berkshire Hathaway Inc Class B trades at $490.09. The key difference: Biogen Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BIIB | BRK.B | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Financials |
52-Week High | $216.63 | $513.70 |
52-Week Low | $122.68 | $459.10 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Berkshire Hathaway Class B shares (BRK.B) trade at $489.92, down 1.38% today, with a bullish technical signal driven by moving averages. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire's diversified holdings and strong cash flow, though key valuation ratios are not provided in the current dataset.
The outlook remains favorable given institutional support and bullish technicals, but risks include market volatility and reliance on broad economic health. Upside potential hinges on continued operational performance across its subsidiaries and strategic capital allocation by management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
